Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
46 studies found for:    ABT-199
Show Display Options
Rank Status Study
1 Withdrawn A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Rifampin
2 Completed A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Ketoconazole
3 Suspended Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Conditions: Lymphoma, Mantle-Cell;   Recurrent Lymphoma, Mantle-Cell
Intervention: Drug: ABT-199 and Ibrutinib Combination
4 Active, not recruiting An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
5 Withdrawn A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
6 Recruiting Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: ABT199
7 Active, not recruiting A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-199;   Drug: Rituximab
8 Active, not recruiting A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: ABT-199
9 Active, not recruiting A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma
Intervention: Drug: ABT-199
10 Completed A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia;   AML;   Acute Myeloid Leukemia
Intervention: Drug: ABT-199
11 Active, not recruiting A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: ABT-199;   Drug: bortezomib;   Drug: dexamethasone
12 Active, not recruiting Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)
Condition: Chronic Lymphocytic Leucemia
Interventions: Drug: Bendamustine;   Drug: GA101;   Drug: ABT-199
13 Active, not recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: ABT-199;   Drug: Dexamethasone
14 Active, not recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
15 Recruiting ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
Condition: Mantle Cell Lymphoma
Interventions: Drug: ABT-199;   Drug: Ibrutinib
16 Recruiting Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Venetoclax;   Drug: Dexamethasone
17 Recruiting Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Conditions: Acute Myelogenous Leukemia;   Myelogenous Leukemia;   Treatment Naive AML
Interventions: Drug: ABT-199;   Drug: Decitabine;   Drug: Azacitidine;   Drug: Posaconazole
18 Active, not recruiting A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
Conditions: Chronic Lymphocytic Leukemia;   17 p Deletion;   Cancer of the Blood and Bone Marrow
Intervention: Drug: ABT-199
19 Completed A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus
Interventions: Drug: ABT-199;   Other: Placebo
20 Recruiting A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib + GA101 +GDC-0199

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.